J Russell Geyer
Affiliation: University of Washington
- Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer GroupJ Russell Geyer
Children s Hospital and Regional Medical Center, Department of Pediatric Hematology Oncology, Seattle, WA 98105, USA
J Clin Oncol 23:7621-31. 2005....
- Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumorsMichael S Bobola
Division of Neurosurgery, Department of Surgery, Children s Hospital and Regional Medical Center, Seattle, WA 98105, USA
Clin Cancer Res 11:7405-14. 2005....
- Gross total resection correlates with long-term survival in pediatric patients with glioblastomaTong Yang
Department of Neurosurgery, School of Public Health, University of Washington School of Medicine, Seattle Children s Hospital, Seattle, Washington, USA
World Neurosurg 79:537-44. 2013..We set out to study patients younger than 18 years of age, carrying the diagnosis of glioblastoma not of the brainstem, their clinical characteristics and clinical factors associated with clinical outcome...
- Cisplatin-based chemotherapy followed by focal, reduced-dose irradiation for pediatric primary central nervous system germinomasJames G Douglas
Department of Radiation Oncology, University of Washington, Seattle, 98195, USA
J Pediatr Hematol Oncol 28:36-9. 2006..6-36 Gy) retains the excellent survival rates for patients with localized, pure germinomas of the CNS. A higher rate of ventricular relapse rate is observed, although salvage of those patients is feasible...
- Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapseBlythe Thomson
Seattle Children s Hospital and Regional Medical Center, Seattle, Washington, USA
Pediatr Blood Cancer 43:571-9. 2004..The ability to achieve a durable second remission is complicated by toxicity and resistant disease. We report a novel combination of chemotherapy for relapsed pediatric ALL...
- DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem gliomaCarlo Giussani
Department of Neurological Surgery, University of Washington School of Medicine, Seattle Children s Hospital, Seattle, WA 98105, USA
Neuroimage 52:217-23. 2010....
- A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomasJ Russell Geyer
Seattle Children s Hospital, Seattle, WA, USA
Eur J Cancer 46:3287-93. 2010....
- Diffusion tensor imaging of the superior cerebellar peduncle identifies patients with posterior fossa syndromeJeffrey G Ojemann
Neurosurgery, Seattle Children s Hospital, Seattle, WA, USA
Childs Nerv Syst 29:2071-7. 2013..Using diffusion tensor imaging (DTI), we examined the involvement of the dentothalamic tracts, specifically the superior cerebellar peduncle (SCP), in patients with posterior fossa tumors and the association with PFS...
- MRI changes associated with vigabatrin treatment mimicking tumor progressionTong Yang
Department of Neurological Surgery, University of Washington School of Medicine, Seattle Children s Hospital, Seattle, Washington, USA
Pediatr Blood Cancer 55:1221-3. 2010..This report highlights the fact that vigabatrin treatment can mimic tumor progression on MRI and confound management of tumors associated with seizures in pediatric patients...
- Adrenocorticotropin-secreting pancreatoblastomaGad B Kletter
Pediatric Endocrine, Swedish Physician Division 1101 Madison, Suite 800, Seattle, WA 98104, USA
J Pediatr Endocrinol Metab 20:639-42. 2007..This malignancy is a rare cause of Cushing's syndrome, particularly at pediatric age. We describe her course including the use of ketoconazole to alleviate hypercortisolemia...
- Spinal cord pilocytic astrocytoma with leptomeningeal dissemination to the brain. Case report and review of the literatureTaylor J Abel
Department of Neurological Surgery, Division of Hematology Oncology, Children s Hospital and Regional Medical Center, University of Washington School of Medicine, Seattle, Washington 98105, USA
J Neurosurg 105:508-14. 2006..This case illustrates a unique instance of supratentorial leptomeningeal dissemination of an intramedullary spinal cord PCA in a child...
- O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell linesMichael S Bobola
Division of Neurosurgery, Department of Surgery and Hematology Oncology, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
Clin Cancer Res 11:2747-55. 2005..Few such data for pediatric glioma lines, particularly those from low-grade tumors, are currently available...
- Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failureJames G Douglas
Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA 98195, USA
Int J Radiat Oncol Biol Phys 58:1161-4. 2004..To review the efficacy and patterns of failure in average-risk medulloblastoma patients treated with concurrent chemotherapy and reduced-dose cranial spinal irradiation and a conformal tumor bed boost...
- Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium reportIan F Pollack
Department of Neurosurgery, Children s Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA
Neuro Oncol 9:145-60. 2007..Imatinib may increase the risk of ITH, although the incidence of spontaneous hemorrhages in brainstem glioma is sufficiently high that this should be considered in studies of agents in which hemorrhage is a concern...
- Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor ConsMark W Kieran
Dana Farber Cancer Institute and Children s Hospital Boston, Boston, MA 02115, USA
J Clin Oncol 25:3137-43. 2007..Primary objectives were to estimate the maximum-tolerated dose (MTD) and to describe the dose-limiting toxicities (DLTs) and pharmacokinetics of lonafarnib. Farnesylation inhibition of HDJ-2 in peripheral blood was also measured...
- Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patientsBurgess B Freeman
Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
Cancer Invest 24:310-7. 2006..Finally, the future for the use of gefitinib in pediatrics is similar to that of other molecularly targeted agents and awaits definition of tumors and patient populations in which it will be most advantageous...
- Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem gliomaDaphne A Haas-Kogan
University of California, San Francisco, San Francisco, CA, USA
Neuro Oncol 10:341-7. 2008..The MTD of tipifarnib with concurrent radiation is 125 mg/m(2)/dose b.i.d. One-year survival and progression-free survival estimates are 36.4% (SE 16.7%) and 9.4% (SE 6.3%), respectively...
- Intrathecal mafosfamide: a preclinical pharmacology and phase I trialSusan M Blaney
Texas Children s Cancer Center, 6621 Fannin St, CC 1410 00, Houston, TX 77030 2399, USA
J Clin Oncol 23:1555-63. 2005..A phase I and pharmacokinetic study of IT mafosfamide was performed to determine a dose for subsequent phase II trials...
- A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952Seema N Sanghavi
Department of Human Oncology, Medical School, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
Neuro Oncol 5:8-13. 2003..50 mg/m(2) x 33 (total dosage = 16.5 mg/m(2)); the recommended safe MTD of daily topotecan for further phase II testing is 0.40 mg/m(2) x 33 (total dosage = 13.2 mg/m(2))...
- Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshopRoger J Packer
Department of Neurology, Children s National Medical Center, The George Washington University Medical Center, Washington, DC 20010, USA
J Pediatr Hematol Oncol 24:337-42. 2002..Therapeutic approached have included surgery, chemotherapy, and radiotherapy. Prospective clinical trials are needed for children with AT/RTs...